Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
University of TX Medical Branch
mi
from
Galveston, TX
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
University of TX Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
UT Health Science Center - San Antonio
mi
from
San Antonio, TX
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
UT Health Science Center - San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Baptist Medical Center
mi
from
Greensboro, NC
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Baptist Medical Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
University of Florida Department of Aging and Geriatrics
mi
from
Gainesville, FL
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
University of Florida Department of Aging and Geriatrics
mi
from
Gainesville, FL
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Phalen Village Clinic
mi
from
Saint Paul, MN
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Phalen Village Clinic
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated:  12/31/1969
Howard University
mi
from
Washington,
Aspirin in Reducing Events in the Elderly
Aspirin in Reducing Events in the Elderly
Status: Enrolling
Updated: 12/31/1969
Howard University
mi
from
Washington,
Click here to add this to my saved trials
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting
Status: Enrolling
Updated:  12/31/1969
Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital
mi
from
Boston, MA
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting
Status: Enrolling
Updated: 12/31/1969
Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Motivational Interviews for Depression in Primary Care
Motivational Interviews Adapted to Improve Depression Treatment in Primary Care
Status: Enrolling
Updated:  12/31/1969
Denver Health and Hospital Authority
mi
from
Denver, CO
Motivational Interviews for Depression in Primary Care
Motivational Interviews Adapted to Improve Depression Treatment in Primary Care
Status: Enrolling
Updated: 12/31/1969
Denver Health and Hospital Authority
mi
from
Denver, CO
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10390
mi
from
Cerritos, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10390
mi
from
Cerritos, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10740
mi
from
Garden Grove, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10740
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 177
mi
from
Imperial, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 177
mi
from
Imperial, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14815
mi
from
Pico Rivera, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14815
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14779
mi
from
Santa Ana, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14779
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 295
mi
from
Sherman Oaks, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 295
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 122
mi
from
Temecula, CA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 122
mi
from
Temecula, CA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12299
mi
from
Gainesville, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12299
mi
from
Gainesville, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 606
mi
from
Jacksonville Beach, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 606
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 021
mi
from
Jacksonville, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 021
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 127
mi
from
Lauderhill, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 127
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10664
mi
from
North Miami, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10664
mi
from
North Miami, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Tampa, FL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 096
mi
from
Atlanta, GA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 096
mi
from
Atlanta, GA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 204
mi
from
Smyrna, GA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 204
mi
from
Smyrna, GA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 107
mi
from
Naperville, IL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 107
mi
from
Naperville, IL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 219
mi
from
Oakbrook Terrace, IL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 219
mi
from
Oakbrook Terrace, IL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 195
mi
from
Park Ridge, IL
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 195
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 600
mi
from
Lafayette, IN
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 600
mi
from
Lafayette, IN
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14747
mi
from
Pikesville, MD
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14747
mi
from
Pikesville, MD
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 603
mi
from
Watertown, MA
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 603
mi
from
Watertown, MA
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 290
mi
from
Flowood, MS
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 290
mi
from
Flowood, MS
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10552
mi
from
Saint Louis, MO
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10552
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 103
mi
from
Mount Laurel, NJ
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 103
mi
from
Mount Laurel, NJ
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Albuquerque, NM
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10187
mi
from
Brooklyn, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10187
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10112
mi
from
Rochester, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10112
mi
from
Rochester, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 110
mi
from
Staten Island, NY
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 110
mi
from
Staten Island, NY
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Raleigh, NC
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 190
mi
from
Beachwood, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 190
mi
from
Beachwood, OH
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10522
mi
from
Canton, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10522
mi
from
Canton, OH
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Cincinnati, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1313
mi
from
Dayton, OH
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1313
mi
from
Dayton, OH
Click here to add this to my saved trials